Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02759406
Other study ID # Mach-5
Secondary ID
Status Completed
Phase N/A
First received April 27, 2016
Last updated April 28, 2016
Start date September 2013
Est. completion date June 2015

Study information

Verified date April 2016
Source Palmaz Scientific
Contact n/a
Is FDA regulated No
Health authority Colombia: National Institutes of Health
Study type Interventional

Clinical Trial Summary

This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date June 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female patients of any race greater than or equal to 18 years and of legal consent

2. Patients must be willing to comply with the specified follow-up evaluation schedule

3. Patients who sign an informed consent (signed and dated) prior to any study-related evaluation or procedure.

4. Patients who are willing to undergo a follow-up coronary angiogram and Endovascular Imaging via Optical Coherence Tomography

5. Patients willing to be maintained on Aspirin and Clopidogrel bisulfate (Plavix) for ninety (90) days post procedure.

6. Patients with a de novo coronary lesion causing angina and/or a positive function test

7. Patients who are eligible for percutaneous coronary interventions

8. Low risk NSTEMI defined as patients with ACS, unstable angina, positive cardiac biomarkers and hemodynamically stable as assessed by the Investigator.

9. Patients with an acceptable risk for coronary bypass graft surgery (CABG)

Intra-Procedure Angiographic Criteria:

1. Single de novo target lesion >50% diameter stenosis by angiography

2. Single target vessel 2.75 to 3.25 mm diameter

3. Lesion length of 14 to 20mm which is suitable for Palmaz Mach-5 Grooved Coronary Stent System or the Palmaz Bare Metal Coronary Stent System.

Exclusion Criteria:

1. Known allergy or sensitivity to cobalt chromium (CoCr) alloy or its components.

2. Known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be pre-treated adequately).

3. Patients unable to tolerate anticoagulant therapy or antiplatelet therapy.

4. History of bleeding or known coagulopathy.

5. Patients with thrombocytopenia and or neutropenia.

6. More than one stenosis >50% in target vessel.

7. Lesion in aortic ostium.

8. Left main or LAD, CX lesions within 2-mm from the origin.

9. Ejection Fraction <45%.

10. STEMI in evolution.

11. Disabling stroke within previous 30 days.

12. Patients currently enrolled in another Investigational device or drug study.

13. Previous enrollment in this study.

14. Women who are currently pregnant. (A negative pregnancy test for female subjects of child bearing potential is required within 24 hours of procedure.)

15. Known or suspected active systemic infection.

16. Evidence of severe or uncontrolled systemic diseases, including chronic renal insufficiency, or any condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
coronary stent


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Palmaz Scientific ClinLogix. LLC

Outcome

Type Measure Description Time frame Safety issue
Primary late lumen loss rate by Quantative/ Qualtative Cornary Angiographia 6 month No
Primary total percentage of strut coverage by Optical Coherence Tomography analysis 6 month No
Primary Primary safety endpoint is the occurrence of adverse events associated with the Investigational and comparator devices. 6 month Yes
Primary binary restenosis rate by Quantative/ Qualtative Cornary Angiographia 6 month No
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A
Completed NCT00983632 - Selective Vagus Nerve Stimulation in Human N/A